23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

“We develop vaccines no one else is developing”

Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
Advertisement

On the third floor of one of the anonymous red-brick buildings next to Karolinska Institutet sits the European office of the International Vaccine Institute (IVI).

This time, Jerome Kim has only managed to catch fleeting glimpses of Stockholm. He is in town for a few days, but his schedule is packed—meetings follow one another, and many are eager to exchange a few words with the Director General during his visit.

Advertisement

Since 2015, Jerome Kim has led the organization. During that time, he built an institution designed to fill a gap often left by the market.

“We develop vaccines that companies don’t want to make. We call them ‘unincentivized market failure vaccines’—vaccines that no one else is developing,” he says.

The European office, with around fifteen employees, plays a strategic role. From here, IVI strengthens its ties to Europe’s global health architecture and European-based organizations such as the WHO, while the time zone also facilitates collaboration with Africa.

Sweden is also IVI’s second-largest governmental funder after South Korea.

“Europe’s voice will become more important as major global funders scale back,” Kim notes, as he welcomes us into a bright conference room overlooking small flags representing IVI member countries.

I miss the lab. tremendously. I took up cooking because it’s the closest I can get to doing lab work

Kim himself was born in Hawaii, into a family deeply connected to modern Korean history. His grandfather emigrated to join the resistance movement against Japan and settled in Hawaii, where many Korean migrants established communities.

Originally trained as a physician at Yale—on a U.S. Air Force scholarship—Kim’s career path was shaped early on.

“I had to pay the military back. They sent me to do HIV vaccine research with the U.S. Army, which is one of the largest funders of HIV vaccine research. That’s how I ended up in vaccines,” he says with a smile.

Advertisement

That assignment marked the beginning of a career spanning both laboratory research and clinical trials.

The U.S. military later sent him to Thailand to conduct a Phase III trial of an HIV vaccine—still the only trial in history to show protection against infection.

When he returned to the U.S., the next step was to understand why it worked.

“We tried to figure out what the vaccine induced that protected people—and we found it.

Despite the promising results, the attention of funders shifted to South Africa, where a different subtype of HIV-1 was predominant and the burden higher—highlighting a recurring challenge in global health that Kim acknowledges: the lack of sustained funding and manufacturing support for vaccines.

Shortly afterwards, Kim took on the role of Director-General of IVI. “It can be frustrating not to see a project through to completion,” he reflects. At the same time, there is something else he misses even more from his time as a researcher.

“I miss the lab. tremendously. I took up cooking because it’s the closest I can get to doing lab work.”

Today, the lab coat has been replaced by a tailored suit. Kim’s work now revolves around ensuring that the entire value chain functions—from research to implementation in resource-limited settings.

Advertisement

“We operate across the whole spectrum. We can develop a vaccine in the lab, test it in animals and humans, work with companies to scale manufacturing, and then, together with WHO and Gavi, deploy it where the need is greatest.”

It is clear that Kim is deeply committed to the field. When discussing the most urgent vaccine needs, he does not point to a lack of innovation—but to a lack of access.

Take hepatitis E, for example—a disease that primarily affects pregnant women in low-income countries. A Chinese vaccine has been approved for over a decade.

“It’s 95% effective. Yet it’s not used in international outbreak responses.”

In such cases, IVI’s role is to generate the evidence needed for WHO to recommend broader use.

Other examples include rotavirus vaccines, and HPV vaccines for cervical cancer.

“Only about 20% of women globally have been vaccinated against a disease that we can essentially eliminate.”

The barriers are not only financial or logistical—they are also structural. In many countries, vaccination programs lose momentum once children reach school age.

To address this, IVI is working to generate data that can shift global recommendations. For HPV vaccines, there are now indications that a single dose may be sufficient.

“That could effectively double the number of doses a country can afford to buy,” Kim says.

Advertisement

Similar mechanisms apply to cholera vaccines. IVI has developed the technology, transferred it to manufacturers, and helped scale production. To date, around 240 million doses have been produced and distributed—while IVI itself has earned only about $1,000 in royalties.

“We don’t take royalties on vaccines used in public health campaigns.”

Looking ahead, Kim highlights more experimental approaches, such as needle-free vaccines delivered via patches.

“No needles. No cold chain. You apply the patch, remove it after five minutes, and you’re vaccinated. You can train someone in a village—no nurses required.”

However, he emphasizes that the technology is still in early stages.

“It looks promising in animals, but it needs to be tested in humans.”

At the same time, the global health landscape is shifting. Vaccines have become increasingly politicized, particularly in the United States.

Under Robert F. Kennedy Jr., vaccine policy has undergone significant changes, with increased politicization of agencies such as the NIH and CDC, replacement of scientific advisors, reduced research funding, and growing skepticism toward established vaccine data—despite strong scientific evidence.

Advertisement

Kim acknowledges a broader tension between science and politics.

“Vaccines are victims of their own success. People don’t see rotavirus deaths, for example, and underestimate the cost of hospital care vs vaccination.”

At the same time, many African countries are responding to reduced U.S. funding by taking greater ownership.

“Funding cutbacks are reducing redundancy and forcing collaboration. It’s painful, but in the long run the system becomes more sustainable as a result.”

In the end, Kim returns to a core principle.

“It should be about science—best data, correct interpretation, peer review, publication—beyond politics.”

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.282|